NO. | Beijing Time (UTC+8) | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
1 | 13:30-13:36 |
The Value of 40 KeV Virtual Monoenergetic Imaging in Preoperative Assessment for Precision TACE in Hepatocellular Carcinoma |
Shuang Li | Zhongda Hospital, Southeast University, China |
2 | 13:36-13:42 |
Efficacy and Safety of Adebrelimab (A PD-L1 Inhibitor) plus Bevacizumab (A VEGF-A-targeting Inhibitor) in Combination with Hepatic Artery Infusion Chemotherapy for Advanced Stage Hepatocellular Carcinoma: A Retrospective Cohort Study |
Chen Li | Sun Yat-sen University Cancer Center, China |
3 | 13:42-13:48 |
A Comparison of Treatment Outcome of Hepatocellular Carcinoma in Caudate Lobe, between Thermal Ablation and Transarterial Chemoembolization: A Retrospective Review |
Sahutchadech Tangisarapap | Roi-Et hospital, Thailand |
4 | 13:48-13:54 |
Efficacy of Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Gallbladder |
Batmunkh Erdenebulgan | Second state central hospital, Mongolia |
5 | 13:54-14:00 |
Percutaneous Cholangioscopy and Fluoroscopy-guided Forceps Biopsy for Pathologically Diagnosing Highly Suspected Perihilar Malignant Diseases: A Retrospective Cohort Study |
Xiang-Yu Yang | Beijing Chao-Yang Hospital, Capital Medical University, China |
6 | 14:00-14:06 |
A Prospective, Single-Arm, Phase 2 Study of Transarterial Embolization plus Hepatic Arterial Infusion Chemotherapy Combined with Sequential Lenvatinib and Sintilimab in Patients with Infiltrative Hepatocellular Carcinoma. |
Ying-Wen Hou | Sun Yat-sen University Cancer Center, China |
7 | 14:06-14:12 |
Efficacy and Safety of TACE Combined with TKI against TACE Alone for Managing Intermediate-stage HCC with Hypovascular Nodules |
Jun Yang | The First Affiliated Hospital of Soochow University, China |
8 | 14:12-14:18 |
First-line Durvalumab with Arterial Chemotherapy in Major Portal Invaded Hepatocellular Carcinoma: the Phase 2 DurHope Study with Biomolecular Analyses |
Ming Zhao | Sun Yat-sen Cancer Center, China |
9 | 14:18-14:24 |
The Prognostic Value of Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio for Liver Tumours after Image-guided Irreversible Electroporation |
Vinson Chan | University of Leeds, United Kingdom |
10 | 14:24-14:30 |
Early Response Evaluation of Hepatocellular Carcinoma After Transarterial Chemoembolization Using Triphasic Computed Tomography |
Nasr ullah Yaqoob | INDUS HOSPITAL KARACHI PAKISTAN, Pakistan |
11 | 14:30-14:36 |
Transarterial Chemoembolization plus Radiofrequency Ablation and Iodine-125 Seed Implantation for Hepatocellular Carcinoma in High-risk Locations |
Guilin Zhang | Wuhan Union Hospital, Huazhong University of Science and Technology, China |
12 | 14:36-14:42 |
Hepatic Arterial Infusion Chemotherapy Combined with Toripalimab and Surufatinib in the Treatment of Advanced Intrahepatic Cholangiocarcinoma |
Songlin Song | Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital, China |
13 | 14:42-14:48 |
Complications of Interventional Treatment for Vascular Tumors and Vascular Malformations: Mechanisms of Occurrence, Treatment Strategies and Prevention |
Qi Wang | Guangdong Provincial People's Hospital, China |
NO. | Beijing Time (UTC+8) | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
1 | 15:00-15:06 |
TACE Combined with Immunotherapy plus Targeted Therapy after 125I Irradiation Stent Placement in HCC with Main Portal Vein Tumor Thrombosis: A Nationwide Target Trial Emulation Study (PATENCY II) |
Jun-Hao Mei | Zhongda Hosiptal, China |
2 | 15:06-15:12 |
Development and Validation of Mean Platelet Volume-Based Predictive Model for Early TACE Failure/Refractoriness in Unresectable Hepatocellular Carcinoma: A Real-World Retrospective Cohort Study |
Hai-Rui Wang | Shengjing Hospital of China Medical University, China |
3 | 15:12-15:18 |
Optimal Thermal Ablation Margin Range Model for Liver Malignancies ≤3 cm Based on 979 Cases |
Zhen-Kang Qiu | Sun Yat-sen University Cancer Center, China |
4 | 15:18-15:24 |
Locoregional Therapy Combined with Systemic Therapy (LRT + ST) for Unresectable and Metastatic Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-analysis |
Zhen-Kang Qiu | Sun Yat-sen University Cancer Center, China |
5 | 15:24-15:30 |
Successful Preoperative Transcatheter Arterial Embolization Significantly Reduces Intraoperative Bleeding in Juvenile Nasopharyngeal Angiofibroma without the Need for Embolization of Internal Carotid Artery Branches: A Case Report of Two Patients |
Stephen Kurniawan | Dr. Cipto Mangunkusumo Hospital-Faculty of Medicine Universitas Indonesia |
6 | 15:30-15:36 |
Lenvatinib plus Hepatic Arterial Infusion Chemotherapy of FOLFOX versus Lenvatinib Alone for Advanced Hepatocellular Carcinoma |
Qi-Cong Mai | Guangdong Provincial People's Hospital, China |
7 | 15:36-15:42 |
Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma : A Bibliometric and Knowledge-map Analysis |
Yu-Qing Xu | Tianjin Medical University Cancer Institute & Hospital,National Clinical Research Center for Cancer, China |
8 | 15:42-15:48 |
Study on the Role of Pirfenidone in Liver Fibrosis - Hepatocellular Carcinoma |
Shuai Zhang | The Affiliated Hospital of Guizhou Medical, China |
9 | 15:48-15:54 |
Hyaluronidase Additional to Transarterial Chemoembolization Improves Efficacy for Liver Cancer: Preclinical Evaluation |
Dan Zhao | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China |
10 | 15:54-16:00 |
Transarterial Chemoembolisation and Tyrosine Kinase Inhibitors with or without Programmed Death-1 Inhibitors as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study |
Xue-Gang Yang | Sichuan Cancer Hospital & Institute, China |
11 | 16:00-16:06 |
Temperature‑sensitive Liquid Embolic Agent Transarterial Chemoembolization (TempSLE-TACE) versus D-TACE for Unresectable Hepatocellular Carcinoma(u-HCC): A Multicenter Retrospective Propensity Score Study in China |
Qingyun Xie | Liver Transplantation Center, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, China |
12 | 16:06-16:12 |
Superselective Ablative Chemo-ethanol Embolization for Recurrent Single Hepatocellular Carcinoma |
Kun Yung Kim | Seoul National University Bundang Hospital, Korea |
13 | 16:12-16:18 |
Efficacy and Prognostic Factors of COVID-19 Vaccine in Patients with Hepatocellular Carcinoma: Analysis of Data from A Prospective Cohort Study |
He Zhao | National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China |
14 | 16:18-16:24 |
HAIC Combined with Sindilizumab and Bevacizumab for the Treatment of Advanced HCC: An Exploratory Clinical Study |
Zizhuo Wang | Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital, China |
15 | 16:24-16:30 |
Integrated Machine Learning Identifies SPP1hi Macrophages Marker Genes for Predicting Therapeutic Response of TACE in HCC |
Zi-Lin Wang | Zhejiang University School of Medicine, China |
NO. | Beijing Time (UTC+8) | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
1 | 16:30-16:36 |
Fruquintinib Combined with Sintilimab plus Transarterial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma (uHCC): A Single-arm Phase Ⅱ Study |
Hui Zeng | Zhejiang Provincial Cancer Hospital, China |
2 | 16:36-16:42 |
Effect of AFP and PIVKA-II Secretion Status on Prognosis of Advanced Hepatocellular Carcinoma Patients Receiving TACE Combined with Systemic Therapies |
Jin-Feng Bai | Yunnan Provincial Cancer Hospital, China |
3 | 16:42-16:48 |
Revolutionizing Detection and Ablation of Invisible Liver Metastases Post-Chemotherapy in Colorectal Cancer: the Role of Transcatheter CT Hepatic Arteriography |
Hang Yuan | Henan Cancer Hospital, China |
4 | 16:48-16:54 |
Yttrium-90 Radioactive Microspheres: Adverse Reactions and Complications of Transcatheter Arterial Radioembolization in the Treatment of Malignant Liver Tumors |
Meng-Di Qi | China Medical University, China |
5 | 16:54-17:00 |
A Study on the Contribution of LSM11 to the Outcome of Radiotherapy in Hepatocellular Carcinoma Cells |
Wen-Yi Jiang | Peking University Cancer Hospital, China |
6 | 17:00-17:06 |
Safety and Technical Feasibility of Modified Percutaneous Transesophageal Enterostomy (PTEE) in Cancer Patients Ineligible for Conventional Gastrostomy |
Ji Hoon Shin | Asan Medical Cente, University of Ulsan College of Medicine, Korea |
7 | 17:06-17:12 |
In Which Tumor Burden Range Does Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors Perform Better than the Combination of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors? A Comparative Analysis of Their Efficacy and Safety in Advanced-stage Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus, Using Propensity Score Matching |
Jia-Xi Liu | The First Hospital of China Medical University, China |
8 | 17:12-17:18 |
Combined Biliary Iodine-125 Brachytherapy and Stent Implantation in Malignant Obstructive Jaundice: A Prognostic Model for Survival Outcomes |
Hui-Yi sun | Interventional Therapy at Zhongshan Hospital, Fudan University, China |
9 | 17:18-17:24 |
CT-guided Celiac Plexus Neurolysis in the Management of Visceral Intractable Pain in Patients with Advanced Cancer |
Tai Tan Nguyen | Nhan Dan Gia Dinh Hospital, Vietnam |
10 | 17:24-17:30 |
Radioactive Iodine-125 Particle Implantation Combined with Transarterial Chemoinfusion and Synchronous Immune Checkpoint Inhibitors for the Management of Locally Advanced Pancreatic Cancer: A Retrospective Single-center Analysis |
Bin Li | Beijing Hospital, China |
11 | 17:30-17:36 |
CT-guided Percutaneous Cryoablation in Patients with Lung Nodules Mainly Composed of Ground-Glass Opacities |
Li-Zhi Niu | Guangzhou Fuda Cancer Hospital, China |
12 | 17:36-17:42 |
The Effect and Mechanism of Iodine 125 Seeds in Combination with Curcumin in Non-Small Cell Lung Cancer |
Zi-Tong Chen | Children's Hospital Alfiliated to Shandong University, China |
13 | 17:42-17:48 |
Ablative Therapy for Residual Lesions After First-Line Treatment of Locally Advanced Unresectable Lung Adenocarcinoma: A Prospective, Randomized Controlled Study |
Feng Xian | Sichuan Cancer Hospital, China |